Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations

Introduction: The effect of disease-modifying therapies (DMT) on vaccine responses is largely unknown. Understanding the development of protective immunity is of paramount importance to fight the COVID-19 pandemic. Objective: To characterise humoral immunity after mRNA-COVID-19 vaccination of people...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Neurology, Neurosurgery and Psychiatry Neurosurgery and Psychiatry, 2021
Main Authors: König, Marton, Lorentzen, Åslaug Rudjord, Torgauten, Hilde Marie, Tran, The Trung, Schikora-Rustad, Stine, Vaage, Eline Benno, Mygland, Åse Daasvand, Wergeland, Stig, Aarseth, Jan Harald, Aaberge, Ingeborg Sundsvalen, Torkildsen, Øivind, Holmøy, Trygve, Berge, Tone, Myhr, Kjell-Morten, Harbo, Hanne-Cathrin Flinstad, Andersen, Jan Terje, Munthe, Ludvig Andre, Søraas, Arne Vasli, Celius, Elisabeth Gulowsen, Vaage, John T, Lund-Johansen, Fridtjof, Nygaard, Gro Owren
Format: Article
Language:English
Subjects:
COVID-19 vaccination
Humoral immunity
Multiple sclerosis
Revaccinations
Side effects
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: The effect of disease-modifying therapies (DMT) on vaccine responses is largely unknown. Understanding the development of protective immunity is of paramount importance to fight the COVID-19 pandemic. Objective: To characterise humoral immunity after mRNA-COVID-19 vaccination of people with multiple sclerosis (pwMS). Methods: All pwMS in Norway fully vaccinated against SARS-CoV-2 were invited to a national screening study. Humoral immunity was assessed by measuring anti-SARS-CoV-2 SPIKE RBD IgG response 3–12 weeks after full vaccination, and compared with healthy subjects. Results: 528 pwMS and 627 healthy subjects were included. Reduced humoral immunity (anti-SARS-CoV-2 IgG